Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS

Gianfranco Meduri, Reed A.C. Siemieniuk, Rachel A. Ness, Samuel J. Seyler

Research output: Contribution to journalLetter

2 Citations (Scopus)

Abstract

An updated meta-analysis incorporating nine randomized trials (n=816) investigating low-to-moderate dose prolonged glucocorticoid treatment in acute respiratory distress syndrome (ARDS) show moderate-to-high quality evidence that glucocorticoid therapy is safe and reduces (i) time to endotracheal extubation, (ii) duration of hospitalization, and (iii) mortality (number to treat to save one life =7), and increases the number of days free from (i) mechanical ventilation, (ii) intensive care unit stay, and (iii) hospitalization. Recent guideline suggests administering methylprednisolone in patients with early moderate-to-severe (1mg/kg/day) and late persistent (2mg/kg/day) ARDS (conditional recommendation based on moderate quality of evidence).

Original languageEnglish (US)
Article number53
JournalJournal of Intensive Care
Volume6
Issue number1
DOIs
StatePublished - Aug 24 2018

Fingerprint

Adult Respiratory Distress Syndrome
Methylprednisolone
Artificial Respiration
Glucocorticoids
Hospitalization
Airway Extubation
Mortality
Intensive Care Units
Meta-Analysis
Guidelines
Therapeutics

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine

Cite this

Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS. / Meduri, Gianfranco; Siemieniuk, Reed A.C.; Ness, Rachel A.; Seyler, Samuel J.

In: Journal of Intensive Care, Vol. 6, No. 1, 53, 24.08.2018.

Research output: Contribution to journalLetter

@article{002ab40b7bea4c198e44d5123ce3fda9,
title = "Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS",
abstract = "An updated meta-analysis incorporating nine randomized trials (n=816) investigating low-to-moderate dose prolonged glucocorticoid treatment in acute respiratory distress syndrome (ARDS) show moderate-to-high quality evidence that glucocorticoid therapy is safe and reduces (i) time to endotracheal extubation, (ii) duration of hospitalization, and (iii) mortality (number to treat to save one life =7), and increases the number of days free from (i) mechanical ventilation, (ii) intensive care unit stay, and (iii) hospitalization. Recent guideline suggests administering methylprednisolone in patients with early moderate-to-severe (1mg/kg/day) and late persistent (2mg/kg/day) ARDS (conditional recommendation based on moderate quality of evidence).",
author = "Gianfranco Meduri and Siemieniuk, {Reed A.C.} and Ness, {Rachel A.} and Seyler, {Samuel J.}",
year = "2018",
month = "8",
day = "24",
doi = "10.1186/s40560-018-0321-9",
language = "English (US)",
volume = "6",
journal = "Journal of Intensive Care",
issn = "2052-0492",
publisher = "Springer International Publishing AG",
number = "1",

}

TY - JOUR

T1 - Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS

AU - Meduri, Gianfranco

AU - Siemieniuk, Reed A.C.

AU - Ness, Rachel A.

AU - Seyler, Samuel J.

PY - 2018/8/24

Y1 - 2018/8/24

N2 - An updated meta-analysis incorporating nine randomized trials (n=816) investigating low-to-moderate dose prolonged glucocorticoid treatment in acute respiratory distress syndrome (ARDS) show moderate-to-high quality evidence that glucocorticoid therapy is safe and reduces (i) time to endotracheal extubation, (ii) duration of hospitalization, and (iii) mortality (number to treat to save one life =7), and increases the number of days free from (i) mechanical ventilation, (ii) intensive care unit stay, and (iii) hospitalization. Recent guideline suggests administering methylprednisolone in patients with early moderate-to-severe (1mg/kg/day) and late persistent (2mg/kg/day) ARDS (conditional recommendation based on moderate quality of evidence).

AB - An updated meta-analysis incorporating nine randomized trials (n=816) investigating low-to-moderate dose prolonged glucocorticoid treatment in acute respiratory distress syndrome (ARDS) show moderate-to-high quality evidence that glucocorticoid therapy is safe and reduces (i) time to endotracheal extubation, (ii) duration of hospitalization, and (iii) mortality (number to treat to save one life =7), and increases the number of days free from (i) mechanical ventilation, (ii) intensive care unit stay, and (iii) hospitalization. Recent guideline suggests administering methylprednisolone in patients with early moderate-to-severe (1mg/kg/day) and late persistent (2mg/kg/day) ARDS (conditional recommendation based on moderate quality of evidence).

UR - http://www.scopus.com/inward/record.url?scp=85052140297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052140297&partnerID=8YFLogxK

U2 - 10.1186/s40560-018-0321-9

DO - 10.1186/s40560-018-0321-9

M3 - Letter

VL - 6

JO - Journal of Intensive Care

JF - Journal of Intensive Care

SN - 2052-0492

IS - 1

M1 - 53

ER -